Adcendo ApS is a clinical-stage biopharmaceutical company headquartered in Copenhagen, Denmark, with US operations in Boston, Massachusetts, developing a new generation of antibody-drug conjugates (ADCs) for cancers with high unmet medical need. Founded in 2017 out of research by Lars Henning Engelholm and Niels Behrendt, the company advances a clinical and pre-clinical pipeline that includes ADCE-T02 (targeting Tissue Factor, in the Phase 1b Tiffany-01 study across advanced solid tumors), ADCE-D01 (targeting uPARAP, granted FDA Fast Track designation for soft tissue sarcoma), and the pre-clinical ADCE-B05. Adcendo is a privately held, venture-backed therapeutics developer; it publishes a corporate website, pipeline and publications pages, and investor press releases, but it operates no developer program, public API, or machine-readable API contract.
Adcendo is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Life Sciences.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/adcendo: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: adcendo
name: Adcendo
description: Adcendo ApS is a clinical-stage biopharmaceutical company headquartered in Copenhagen, Denmark, with US operations
in Boston, Massachusetts, developing a new generation of antibody-drug conjugates (ADCs) for cancers with high unmet medical
need. Founded in 2017 out of research by Lars Henning Engelholm and Niels Behrendt, the company advances a clinical and
pre-clinical pipeline that includes ADCE-T02 (targeting Tissue Factor, in the Phase 1b Tiffany-01 study across advanced
solid tumors), ADCE-D01 (targeting uPARAP, granted FDA Fast Track designation for soft tissue sarcoma), and the pre-clinical
ADCE-B05. Adcendo is a privately held, venture-backed therapeutics developer; it publishes a corporate website, pipeline
and publications pages, and investor press releases, but it operates no developer program, public API, or machine-readable
API contract.
url: https://raw.githubusercontent.com/api-evangelist/adcendo/refs/heads/main/apis.yml
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
image: https://adcendo.com/wp-content/uploads/adcendo-logo.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Life Sciences
- Antibody-Drug Conjugates
- Clinical Stage
- Denmark
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/adcendo-domain-security.yml
- type: Website
url: https://adcendo.com/
- type: About
url: https://adcendo.com/adcendo/about/about-adcendo/
- type: Pipeline
url: https://adcendo.com/adcendo/our-science/pipeline/
- type: Publications
url: https://adcendo.com/adcendo/our-science/key-publications/
- type: PressReleases
url: https://adcendo.com/adcendo/investors/press-releases/
- type: BlogRSS
url: https://adcendo.com/feed/
- type: Careers
url: https://adcendo.com/adcendo/your-careers-and-our-values/
- type: Contact
url: https://adcendo.com/contact/
- type: PrivacyPolicy
url: https://adcendo.com/privacy-policy/
- type: CookiePolicy
url: https://adcendo.com/cookie-policy/
- type: LLMsTxt
url: llms/adcendo-llms.txt
x-enrichment:
date: '2026-08-06'
status: minimal
artifacts_added: 2
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: Adcendo is a clinical-stage biopharmaceutical company developing antibody-drug conjugates; its only machine-readable
endpoint is the stock WordPress REST API of its marketing CMS at /wp-json/ (LiteSpeed, Wordfence, Divi and Google Site
Kit plugin routes), and every OpenAPI, GraphQL, MCP and A2A discovery path on adcendo.com returns 404.
evidence:
- url: https://adcendo.com/openapi.json
status: 404
- url: https://adcendo.com/graphql
status: 404
- url: https://adcendo.com/.well-known/agent-card.json
status: 404
- url: https://adcendo.com/.well-known/security.txt
status: 404
- url: https://adcendo.com/wp-json/
status: 200
checked: '2026-08-06'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.